41
DAFTAR PUSTAKA
1. Theise ND. Hati, kandung empedu dan saluran bilier. In: Nassar IM, Cornain S, editors. Buku ajar patologi robbins edisi Bahasa Indonesia .9th ed.Singapura: Saunders Elsevier; 2015. p. 604-610.
2. Kementerian Kesehatan Republik Indonesia.Badan Penelitian dan Pengembangan Kesehatan : Riset kesehatan dasar 2013. Kementerian Kesehatan Republik Indonesia:2013. p. 71-72
3. Hanafiah MK, Groeger J,Flaxman DA, Wiersma ST.Global epidemiology of hepatitis C Virus Infection : new estimates of age-specific antibody to HCV seroprevalance. J American Association for Study of Liver Diseases.2013 Apr 57(4):1333-1342.
4. Gani AR. Hepatitis C. In : Setiati S, Alwi I, Sudoyo AW, Marcelius SK, Setiyahadi B, Syam AF, editors. Ilmu penyakit dalam Jilid II.6th ed. Jakarta; Pusat Penerbitan Ilmu Penyakit Dalam; 2014. p. 1972-1977.
5. Kementrian Kesehatan Republik Indonesia. Pedoman pengendalian hepatitis virus.Kementrian Kesehatan Republik Indonesia;2012. p.19-25.
6. Chang IC, Huang SF, Chen PJ,Chen CL,editors et al. The hepatitis viral status in patients with hepatocellular carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.Medicine J.2016 Nov 95(15):1-9.
7. Davis LG, Alter JM, El-Serag H,Poynad T, Jennings LW.aging of hepatitis C virus (HCV)-infected persons in United States : a multiple cohort model of HCV prevalance and disease progression. J American Gastroenterological Association.2010 feb 138(2):513-521.
8. Kementerian Kesehatan Republik Indonesia.Peraturan Menteri Kesehatan Indonesia Nomor 53 Tahun 2015.Kementerian Kesehatan Republik Indonesia;2015. p.28-31.
9. Snell RS. Sistem pencernaan. In: Suwahjo A, Lyestiawan YA, editors. Anatomi klinis Berdasarkan sistem. Jakarta:EGC;2011. p. 722 - 730.
10.Nguyen TT, Liangappa VR. Penyakit hati. In: Dany F, editors. Patofisiologi penyakit pengantar menuju kedokteran klinis. Jakarta:ECG;2011. p.421-453
11.Mescher AL.Organ-organ yang berhubungan dengan saluran cerna. In : Hartanto H, editors. Histologi dasar junqueira teks dan atlas.12thed.Jakarta.EGC;2011. p. 282 – 290.
42
12.Netter FH. Abdomen. In: Atlas of Human Anatomy.5thed .Saunders Elsevier,2010. p. 277.
13.Eroschenko VP, Editors. Sistem Pencernaan: hati, kandung empedu, dan pankreas. In: Dharmawan D, Yesdelita N. Atlas histologi diFiore dengan korelasi fungsional.11th ed.Jakarta. ECG;2012. p. 332-333.
14.Messina JP,Humphreys I,Flaxman A, Brown A, Cooke GS,Pybus OG, Barnes E.Global distribution and prevalance of hepatitis C virus genotype. J American Association for Study of Liver Diseases.2015 Jan 61(1):77-87.
15.Tohme RA, Holmberg SD, Is sexual contact a major mode of hepatitis C virus transmision?. J American Association for Study of Liver Diseases.2010Oct 52(4):1497-1505.
16.Liang TJ, Rehermann B,Seeff LB,Hoofnagle JH. Pathogenesis, natural history,treatment,and prevention of hepatitis C.J Ann Intern Med.2000 Feb 132(4):296-305.
17.World Health Organization.Guidelines for screening care and treatment of persons with hepatitis C infection.World Health Organization;2014. p. 30-31.
18.Jason MH, Sud A,Geoffrey CF,Bandara P, Byth K, James GK,GeoffreyWM,George J.Insulin resistance is associates with chronic hepatitis Cvirus infection and fibrosis progression.J American Gastroenterological Association.2003 Dec 125(6):1695-1704.
19.Missiha SB, Ostrowski M,Heathcote EJ.Disease Progression in chronichepatitis C: modifiable and nonmodifiable factors. J American Gastroenterological Association.2008 May 134(6):1699-1714.
20.European Association for Study of the Liver. EASL recommendation on treatment of hepatitis C 205.European Association for Study of the Liver;2015. p. 199-217.
21.Interna Publishing. Hepatologi. In: Alwi I, Salim S, Hidayat R, Kurniawan J, Tahapary DL, editors. Penatalaksaan di bidang Ilmu penyakit dalam panduan praktik klinis.jakarta.Pusat Penerbitan Ilmu PenyakitDalam;2014. p. 240- 241.
22.Asian Pasiffic Association for the Study of Liver. APASL consensus statements and recommendation on treatment of hepatitis C.Asian Pasiffic Association for the Study of Liver;2016. p. 4-15.
23.American Association for the Study of Liver Diseases.Hepatitis Guidance : AASLD-IDSA recommendations for testing, managing,and treating
43
adultsinfected with hepatitis C virus.American Association for the Study of Liver Diseases;2015. p. 937- 941.
24.Pearlman BL, Traub N.Sustained virologic response to antiviral therapy for chronic hepatitis C Virus Infection: A cure and So Much More.J Oxford University.2011 Sep 52(7): 889-900.
25.Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C Virus infected population in the United States.BMC Infectious Diseases[Internet]. 2012 Apr [cited 24 Mei
2016]:12(86) Available from Medscape
26. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca A, Piazza M. Prevalance, risk Factors, and genotype of hepatitis C virus infection in general population : A community-based survey in southern Italy. 1997 May 26(4): 1006-1001.
27.Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt : a systematic review and data synthesis. J BMC Infectious Diseases. 2013 June [cited 5 Dec 2016]
Avalailable from Biomed Central
28.Butterfield ML, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC, Goodman LA, Swanson JW, Bastian LA, Horner RD. Blood Borne Infections and Persons with mental illness : Gender differences in hepatitis C infection and risks amon persons with sever mental illness. J psychiatry online. 2003 June 54(6): 848-853.
29.Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E, Pawlostky J, Dhumeaux D, Lotersztajin S, Maliat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. J American Association for the Study of Liver Diseases 2005 May 42(1) : 63-71.
30.Pessione F, Ramond M, Njampoum C, Duchtelle V, Degott C, Erlinger S, Rueff B, Valla D, Degos F. Cigarette smoking and hepatic lesion in patients with chronic hepatitis C.J American Association for the Study of Liver Diseases. 2001 July 34(1) : 121-12.
31.Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalance of type 2 diabetes melitus among person with hepatitis C virus infection in the united states. J Ann Intern Med.2000 Oct 133(8) 592-599.
44
32.Wai CT, Greenson JK, Fontana RJ, Kalbfeisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. J American Association for the Study of Liver Diseases. 2003 Mei 38(2): 518-526.
33.Pockros PJ, Duchini A, McMilan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. 2002 Aug 97(8): 2040-5.
34.Fouad YM. Chronic hepatitis C –associated thrombocytopenia: aetiology and management. J Tropical Gastroenterlogy and Endemic Medicine. 2013 34(2):58-67
35.Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Antiviral Therapy in HCV-infected Decompensated Cirrotics. J Saudi Gastroenterol. 2010 Oct 16(4): 310-314.
36.Zein NN. Clinical significance of hepatitis C virus genotypes. J Mayo Clinic and Mayo Foundation. 2000 Apr 13(2): 223-35.
37.Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J European Association for Study of the Liver. 2012 May 56(5):1711-1180.
38.Fried MW. Side effect of Therapy of Hepatitis C and Their management. . J American Association for the Study of Liver Diseases. 2002 36(5) 237-234.
39.Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and disease progression, A review of the most recent literature. 2011 Nov 6(6): 478-482.
40. Ashgar HA, Helmy A, Khan MQ, Kahtani KA, Quaiz MA, Rezeig M, Kagevi I, Alshehri A, Kalbani AA, Swat KA, Dahab S. Predictors of sustained virological response to a 48 week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. 2009 Jan-Feb 29(1): 4-14.
